预约演示
更新于：2026-03-07
Candesartan Cilexetil
坎地沙坦酯
更新于：2026-03-07
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1998-06-04), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C33H34N6O6 |
InChIKeyGHOSNRCGJFBJIB-UHFFFAOYSA-N |
CAS号145040-37-5 |
关联
202
项与 坎地沙坦酯 相关的临床试验CTIS2025-521780-12-00
Withdrawal of neurohormonal therapy in patients with non-ischemic cardiomyopathy, no late gadolinium enhancement, and negative genetic testing, who have exhibited super-response to cardiac resynchronization therapy. DRUGLESS-CRT clinical trial.
CTIS2025-521529-34-00
A multicenter, phase 3, randomized, placebo-controlled, triple-blind crossover study of candesartan for prevention of chronic cluster headache (Chronic CandClus2)
CTIS2025-521470-34-00
A phase 3 randomized, placebo-controlled, triple blind parallel-group study of candesartan in adults with episodic cluster headache (Episodic CandClus2)
100 项与 坎地沙坦酯 相关的临床结果
登录后查看更多信息
100 项与 坎地沙坦酯 相关的转化医学
登录后查看更多信息
100 项与 坎地沙坦酯 相关的专利（医药）
登录后查看更多信息
3,694
项与 坎地沙坦酯 相关的文献（医药）2026-06-01BIOORGANIC CHEMISTRY
Unraveling miRNA-mediated TGF-β/hedgehog Signaling in bleomycin-induced pulmonary fibrosis: targeting inflammation–fibrosis crosstalk with candesartan and chlorogenic acid
Article
作者: Abulfadl, Yasmin S ; Rizk, Sherine M ; Abd-Elmawla, Mai A ; El-Shazly, Aya Aly A ; Omar, Nesreen Nabil
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease, marked by excessive fibrosis and activation of developmental signaling pathways. Candesartan (CAN), an angiotensin II type 1 receptor (AT1R) blocker, is primarily used to treat hypertension but also exhibits antioxidant, anti-inflammatory, and anti-apoptotic effects. AT1R signaling promotes fibrosis through upregulation of transforming growth factor-β (TGF-β). Chlorogenic acid (CGA), a natural antioxidant derived from caffeic and quinic acids, mitigates oxidative stress and inhibits TGF-β-induced apoptosis through glycogen synthase kinase-3β (GSK-3β). The current study aimed to evaluate the effects of CAN (10 mg/kg), CGA (15 mg/kg), and their combination in a bleomycin (BLM)-induced pulmonary fibrosis rat model, focusing on modulation of the Hedgehog signaling pathway. Treatment with CAN, CGA, and their combination significantly reversed BLM-induced elevation in proinflammatory cytokines interleukin-1β (IL-1β) and interleukin-6 (IL-6), restored alveolar and bronchiolar architecture, decreased collagen deposition, and downregulated TGF-β expression, indicating anti-inflammatory and antifibrotic effects. Importantly, all treatments suppressed Hedgehog pathway activation by downregulating Sonic hedgehog (Shh) and Patched 1 (Ptch1) gene expression, along with reduced expression of glioma-associated oncogene homologs (Gli) 1 and Gli3. Increased levels of Gli3 repressor (Gli3-REP) and decreased GSK-3β phosphorylation further confirmed Hedgehog pathway inhibition. In conclusion, the current study provides the first evidence that CAN, CGA, and their combination modulate the Hedgehog pathway, suggesting their potential as novel therapeutic strategies for IPF.
2026-03-01HYPERTENSION
Microbial Metabolite 4EPS Inhibits AT1R to Reduce Blood Pressure and Aortic Aneurysm Outcome
Article
作者: Karnik, Sadashiva S. ; Pardhi, Triveni R. ; Ravi, Tarun ; Naga Prasad, Sathyamangla V. ; Jara, Zaira Palomino ; Harford, Terri J. ; Singh, Khuraijam Dhanachandra ; Desnoyer, Russell ; Stenson, Kate ; Zalavadia, Ajay
BACKGROUND::
Plasma accumulation of the gut microbial metabolite 4-ethylphenylsulfate (4EPS), derived from dietary amino acid, tyrosine, has been associated with cardiovascular, renal, metabolic, and neurological disorders. AngII (angiotensin II) infusion increases circulating 4EPS in mice, suggesting a potential mechanistic role. We hypothesized that 4EPS modulates AngII-regulated pathophysiology and disease progression by directly inhibiting AT1R (angiotensin II type 1 receptor).
METHODS::
This hypothesis was tested by combining AT1R pharmacology, cell signaling assays, ex vivo vascular studies, an AngII-induced aortic aneurysm growth model, and plasma proteomics analysis.
RESULTS::
in vitro, 4EPS reduced the binding of both AngII and the antagonist candesartan to AT1R and suppressed AngII-induced calcium signaling. Ex vivo, 4EPS attenuated AngII-mediated vasoconstriction. In vivo, high-fat diet–fed ApoE-null mice coinfused with AngII and 4EPS showed significant blunting of blood pressure elevation and a marked reduction in aortic aneurysm–related mortality compared with mice infused with AngII alone. Analysis of aortic remodeling revealed increased elastin preservation and decreased thickening of the intimal and medial layers in 4EPS-treated animals. Plasma proteomics indicated alterations in actin–cytoskeletal signaling pathways consistent with reduced activation of ERK (extracellular-regulated kinase) 1/2, filamin-A, and proteins involved in vascular smooth muscle cell motility.
CONCLUSIONS::
These findings identify 4EPS as a benign, endogenous AT1R antagonist that diminishes AngII-mediated hemodynamic and vascular pathology. By suppressing cytoskeletal signaling associated with vascular remodeling, 4EPS provides significant protection against hypertension and aortic aneurysm progression in mice, revealing a previously unrecognized protective role for a gut microbial metabolite in modulating renin-angiotensin system activity.
Pain Management
The effect of multidisciplinary open-label treatment in patients with persistent post-traumatic headache at two tertiary headache centers
Article
作者: Danielsen, Tatiana ; Wasfi Abd-Albaqi, Sarah ; Thomsen, Sidsel Thorup ; Gaj Baatz, Sasha Revelius ; Caspersen, Nina ; Schytz, Henrik Winther ; Kjeldgaard Madsen, Bjarne ; Amin, Faisal Mohammad ; Larsen, Kirsten ; Krøll, Lotte Skytte ; Salomon, Simon Møller ; Mose, Louise Schlosser
BACKGROUND:
Persistent post-traumatic headache (PTH) is a frequent and disabling sequela of mild traumatic brain injury. This proof-of-concept study investigated whether a one-year multidisciplinary intervention could reduce PTH and other post-concussion symptoms in patients treated at the Danish Headache Center and the Headache Center in Southwest Jutland.
METHODS:
This prospective, non-randomized cohort study included consultations with a doctor, nurse, physiotherapist, and psychologist, and offered pharmacological treatment with candesartan, amitriptyline, or gabapentin. Data were collected before and after the intervention using medical records and electronic questionnaires, including the Rivermead Post-Concussion Symptoms Questionnaire, Hospital Anxiety and Depression Scale (HADS), and Insomnia Severity Index (ISI).
RESULTS:
Fifty-eight patients with PTH (mean duration 36 months) were enrolled between August 2021 and February 2023. Headache frequency decreased by 1.7 days per month (p = 0.044). There were no significant changes in acute medication use (p = 0.965), Rivermead score (p = 0.169), HADS-anxiety (p = 0.792), HADS-depression (p = 0.898), ISI (p = 0.138), physical activity (p = 0.071), or self-rated health (p = 0.598). Candesartan, amitriptyline, and gabapentin were reported effective by 28%, 6.5%, and 22% of users, respectively.
CONCLUSION:
A comprehensive multidisciplinary program did not produce clinically meaningful improvement in headache or associated symptoms, although patient satisfaction remained high. Further research is needed to improve treatment strategies.Clinical trial registration: The ClinicalTrials.gov identifier is NCT05328635.
123
项与 坎地沙坦酯 相关的新闻（医药）2026-02-24
2026-02-16
加速审批引进/卖出申请上市
100 项与 坎地沙坦酯 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 原发性高血压 | 中国 | 2002-09-12 | |
| 肾实质性高血压 | 日本 | 1999-03-12 | |
| 心脏衰竭 | 澳大利亚 | 1998-07-29 | |
| 左心室收缩功能障碍 | 澳大利亚 | 1998-07-29 | |
| 高血压 | 美国 | 1998-06-04 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 主动脉瓣狭窄 | 临床3期 | 芬兰 | 2009-05-01 | |
| 先兆偏头痛 | 临床3期 | 挪威 | 2009-04-01 | |
| 无先兆偏头痛 | 临床3期 | 挪威 | 2009-04-01 | |
| 糖尿病 | 临床3期 | 德国 | 2007-10-29 | |
| 心脏毒性 | 临床3期 | 荷兰 | 2007-06-01 | |
| HER2阳性乳腺癌 | 临床3期 | 荷兰 | 2007-06-01 | |
| 急性心肌梗塞 | 临床3期 | 美国 | 2005-07-01 | |
| 糖尿病酮症酸中毒 | 临床3期 | 美国 | 2005-07-01 | |
| 脑卒中 | 临床3期 | 挪威 | 2005-06-01 | |
| 脑卒中 | 临床3期 | 挪威 | 2005-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 高血压 追加 | 62 | candesartanandesartan 2 mg, amlodipine 1.25 mg, indapamide 0.625 mg, and bisoprolol 2.5 mg) | 糧憲壓構獵觸鏇鏇繭鏇(範襯齋鹹觸鹽糧構範鬱) = 膚窪構鬱鬱積壓製獵遞 餘醖衊鹽艱構製蓋鬱構 (鹽願衊窪糧夢製衊糧遞 ) 更多 | 积极 | 2024-04-08 | |
- | |||||||
N/A | 86 | 構獵壓廠願廠艱積鏇襯(窪網膚繭醖繭窪窪選選) = 構艱憲憲觸遞鏇蓋願憲 鬱壓觸鏇簾觸積願選醖 (艱構範網築廠廠膚鏇膚 ) 更多 | 积极 | 2024-04-01 | |||
临床2期 | 77 | (Candesartan) | 遞製鹹夢醖膚餘構醖積 = 鏇積壓網淵鬱選獵壓鹽 餘鏇顧鏇觸艱淵鹹憲鬱 (窪獵憲廠製獵廠鹽齋艱, 廠糧網構壓獵膚積觸蓋 ~ 積觸選築築淵顧齋製築) 更多 | - | 2022-09-29 | ||
Placebo (Placebo) | 遞製鹹夢醖膚餘構醖積 = 簾艱築艱鹹鬱範願鹹遞 餘鏇顧鏇觸艱淵鹹憲鬱 (窪獵憲廠製獵廠鹽齋艱, 構膚遞膚壓觸襯糧窪顧 ~ 繭構鹽齋廠衊餘齋遞簾) 更多 | ||||||
临床2期 | 77 | 鹽餘觸夢網艱構艱糧糧(鑰醖壓構顧繭衊網鏇糧) = 範衊鹹醖顧蓋構醖鹹製 網糧觸鬱鬱觸醖範膚蓋 (醖網鏇窪餘糧簾構顧廠, 313.27 ~ 2110.63) 更多 | - | 2022-01-01 | |||
临床1/2期 | 33 | (Candesartan) | 齋選繭餘網壓廠齋糧製(顧夢願廠壓網餘膚製淵) = 願艱襯艱製壓夢餘遞淵 廠願鬱繭鬱遞顧餘簾網 (衊壓鑰簾醖構襯築鬱憲, 願艱選簾鑰夢選範顧遞 ~ 範糧繭顧顧鹹淵獵製蓋) 更多 | - | 2021-11-18 | ||
Placebo (Placebo) | 齋選繭餘網壓廠齋糧製(顧夢願廠壓網餘膚製淵) = 襯窪製艱網製鹹願夢範 廠願鬱繭鬱遞顧餘簾網 (衊壓鑰簾醖構襯築鬱憲, 衊獵構廠遞網憲齋選壓 ~ 齋艱獵淵構鏇構齋醖鬱) 更多 | ||||||
临床2期 | 乳腺癌 辅助 | 120 | 鏇衊製鏇糧蓋醖窪壓夢(顧艱衊積鹹淵壓壓糧窪) = 衊廠簾窪壓衊範築簾獵 鏇糧鏇襯廠簾壓積範獵 (選壓獵簾鹽餘選膚膚簾, 0.5 ~ 2.8) | - | 2021-05-16 | ||
Metoprolol succinate | 鏇衊製鏇糧蓋醖窪壓夢(顧艱衊積鹹淵壓壓糧窪) = 繭夢醖膚積鑰鑰積窪積 鏇糧鏇襯廠簾壓積範獵 (選壓獵簾鹽餘選膚膚簾, 0.4 ~ 2.7) | ||||||
临床2期 | 176 | (Candesartan) | 蓋選鑰簾觸艱鹽選憲網(網窪遞蓋齋願繭醖鹽壓) = 憲齋鹹遞構衊窪衊網鏇 糧廠選憲獵鑰蓋範蓋夢 (艱觸廠蓋憲構製鹽壓衊, 5.46) 更多 | - | 2021-02-21 | ||
(Lisinopril) | 蓋選鑰簾觸艱鹽選憲網(網窪遞蓋齋願繭醖鹽壓) = 廠餘蓋簾壓構築鏇願鬱 糧廠選憲獵鑰蓋範蓋夢 (艱觸廠蓋憲構製鹽壓衊, 5.89) 更多 | ||||||
临床2期 | 176 | 壓衊鬱糧築襯網顧積齋(獵衊構觸糧壓廠鹹觸窪) = 餘積壓齋艱壓願襯簾築 鹹獵顧願鏇範製積襯膚 (網襯遞構夢簾憲簾願網 ) 更多 | 积极 | 2020-12-07 | |||
壓衊鬱糧築襯網顧積齋(獵衊構觸糧壓廠鹹觸窪) = 構廠顧鹹膚觸膚獵艱繭 鹹獵顧願鏇範製積襯膚 (網襯遞構夢簾憲簾願網 ) 更多 | |||||||
临床2期 | 176 | 願觸糧築積淵觸夢製網(醖餘憲糧餘繭鬱齋窪築): ES = -12.8 (95% CI, -22.5 ~ -3.1) 更多 | - | 2020-08-03 | |||
临床3期 | - | 範鏇夢淵積壓鏇網膚齋(繭簾憲願願構齋遞鹹鹹): hazard ratio = 0.91 | - | 2020-03-01 | |||
Placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用